Procollagen type III amino-terminal propeptide: A serum biomarker of left ventricular remodelling in paediatric dilated cardiomyopathy

Cardiology in the Young

Volumn 25, Issue 2, 2015, Pages 228-236

  Kaufman, Beth D ^a   Videon, Nancy ^b   Zhang, Xuemei ^b   Harris, Matthew A ^c   Shaddy, Robert E ^c   Goldmuntz, Elizabeth ^c  

^a LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biomarker; cardiac remodelling; cardiomyopathy; collagen III; myocarditis

Indexed keywords

PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE REMODELING; HEART VENTRICLE SIZE; HUMAN; LONGITUDINAL STUDY; MALE; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ADOLESCENT; BLOOD; COHORT ANALYSIS; ECHOGRAPHY; PRESCHOOL CHILD;

ADOLESCENT; BIOMARKERS; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MYOCARDITIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSPECTIVE STUDIES; VENTRICULAR REMODELING;

EID: 84927602559     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951113001820     Document Type: Article

References (32)

1. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348: 1647-1655.
2. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348: 1639-1646.
3. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 2003; 24: 280-288.
4. Wilkinson JD, Landy DC, Colan SD, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Failure Clinics 2010; 6: 401-413.
5. Xie SB, Yao JL, Zheng SS, Yao CL, Zheng RQ. The levels of serum fibrosis marks and morphometric quantitative measurement of hepatic fibrosis. Hepatobiliary Pancreat Dis Int 2002; 1: 202-206.
6. Lijnen PJ, Petrov VV. Role of intracardiac renin-angiotensinaldosterone system in extracellular matrix remodeling. Methods Find Exp Clin Pharmacol 2003; 25: 541-564.
7. Berry C, Murphy N, De Vito G, et al. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 2007; 9: 429-434.
8. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54: 1674-1682.
9. Radauceanu A, Ducki C, Virion J-M, et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008; 14: 467-474.
10. Barasch E, Gottdiener JS, Aurigemma G, et al. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly/clinical perspective. Circ Heart Fail 2011; 4: 733-739.
11. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227-1232.
12. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation 2000; 102: 2700-2706.
13. Rutschow S, Li J, Schultheiss HP, Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 2006; 69: 646-656.
14. Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995; 75: 913-918.
15. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004; 6: 539-545.
16. Lin YH, Lin C, Lo MT, et al. The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death. Clin Chem Lab Med 2010; 48: 1821-1827.
17. Crofton PM, Ahmed SF, Wade JC, et al. Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr Res 2000; 48: 490-496.
18. Crofton PM, Ahmed SF, Wade JC, et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998; 83: 3121-3129.
19. Crofton PM, Wade JC, Taylor MR, Holland CV. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem 1997; 43: 1577-1581.
20. Doherty CP, Crofton PM, Sarkar MA, et al. Malnutrition, zinc supplementation and catch-up growth: changes in insulin-like growth factor I, its binding proteins, bone formation and collagen turnover. Clin Endocrinol 2002; 57: 391-399.
21. Trivedi P, Hindmarsh P, Ristell J, Ristell L, Mowat AP, Brook CGD. Growth velocity, growth hormone therapy, and serum concentrations of the amino-terminal propeptide of type III procollagen. J Pediatr 1989; 114: 225-230.
22. Spagnoli A, Branca F, Spadoni GL, et al. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment. J Clin Endocrinol Metab 1996; 81: 3589-3593.
23. Grenier MA, Osganian SK, Cox GF, et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J 2000; 139 (Pt 3): S86-S95.
24. Orion Corporation. Orion Diagnostica. UniQ PIIINP N-Terminal Propeptide of Type III Procollagen Radioimmunoassay Kit Catalogue No. 06098. Orion Corporation, Espoo, Finland, 2003.
25. Cicoira M, Rossi A, Bonapace S, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004; 10: 403-411.
26. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565.
27. Rossi A, Cicoira M, Golia G, et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart 2004; 90: 650-654.
28. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000; 101: 1527-1532.
29. Zile MR, Desantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011; 4: 246-256.
30. Hayashi M, Tsutamoto T, Wada A, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1375-1382.
31. Hsia T-Y, Ringewald JM, Stroud RE, et al. Plasma profiling determinants of matrix homeostasis in paediatric dilated cardiomyopathy. Cardiol Young 2011; 21: 52-61.
32. Foerster SR, Canter CE, Cinar A, et al. Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry. Circ Heart Fail 2010; 6: 689-697.